709 filings
Page 2 of 36
S-8 POS
xfkn1xww t6qvu1iz
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:51pm
S-8 POS
y2phmx9gji4hbiml
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:51pm
S-8 POS
v14cfb62
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:50pm
S-8 POS
gjnvy9jltatcm58pul
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:50pm
S-8 POS
wft e5mfkyefepszpssj
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:49pm
S-8 POS
7a6xh9g3
26 Jan 23
Registration of securities for employees (post-effective amendment)
8:49pm
25-NSE
ndhy8ebray wx2
25 Jan 23
Exchange delisting
9:23am
8-K
cv8336ii7zvsq63kd u1
18 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:32am
8-K
7osi54d92ahoiszta
17 Jan 23
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
6:20am
8-K
anoz6co48
15 Dec 22
Viveve Announces Completion of Pivotal U.S. PURSUIT Trial
8:29am
8-K
kut45k6f0j
2 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:12pm
8-K
c8w y1lz6s5sl
1 Dec 22
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
8:29am
8-K
ouvjv
23 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
j19x7c 7fvo
10 Nov 22
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:03pm
D
q2upm4 uh1p0he4v9mx7
26 Oct 22
$14.68 k in equity, sold $14.68 k, 1 investor
6:58pm
8-K
00yf6acs
4 Oct 22
Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
8:29am
EFFECT
j8p2u5w1i xtuej6
29 Sep 22
Notice of effectiveness
12:15am